LY-3185643
Highest phase reached
Phase 1
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Protein
- Drug name
- LY-3185643
- ly 3185643
- Ly-3185643
- LY-3185643
- ly3185643
- Ly3185643
- LY3185643
- LY3185643 (Part B)
- ChEMBL ID
- CHEMBL4298019
- FDA ingredient codes (UNII)
- 32SI0A8R0O
- First in class
- No
- Orphan designation
- No
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (61)
- [11C]Carfentanil PET Study of GSK1521498
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
- A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
- A Study Assessing HMB-002 in Participants With Von Willebrand Disease
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
- A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
- A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
- A Study of AZD8233 in Participants With Dyslipidemia.
- A Study of LY3143753 and LY3185643 in Healthy Participants
- A Study of LY3185643 and rGlucagon in Healthy Participants
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
- A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
- A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers